Pharma BD Deal Intelligence
Pfizer's $650M upfront (up to $4.2B) for Orgovyx co-commercialization survived Myovant's own 2023 buyout by Sumitovant intact, backed by a trial showing a 54% cut in major adverse cardiovascular events versus leuprolide.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →In this Phase 3 trial of 934 men with advanced prostate cancer, oral relugolix achieved sustained testosterone suppression in 96.7% of men compared with…
Pfizer is paying Myovant $650 million up front to co-commercialize the oral prostate cancer drug Orgovyx in the U.S. and Canada. The deal builds on Pfizer's…
Sumitovant to acquire all outstanding Myovant shares not already owned for $27.00/share cash ($1.7B; ~$2.9B total company value); Myovant to become a wholly…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Myovant and Pfizer announced a US/Canada collaboration to jointly develop and commercialize Orgovyx (relugolix) in advanced prostate cancer and relugolix combination tablet in women's health. Myovant received $650M upfront plus $200M regulatory milestones for relugolix combo tablet women's health approvals and tiered sales milestones up to $3.5B+, total deal up to $4.2B. Profits and certain expenses split 50/50 with Myovant booking revenue. Post-close development: in October 2022 Sumitovant Biopharma (Sumitomo Pharma group), which already held a majority stake, agreed to acquire the remaining Myovant shares at $27.00/share ($1.7B; ~$2.9B total company value); the deal completed March 10, 2023, making Myovant a wholly owned Sumitovant subsidiary and delisting it from the NYSE. The Pfizer collaboration was not terminated and continues under Myovant as a Sumitomo subsidiary.
Assessment window: 5yr post-close.
249K US cases/yr · $9.5B US prostate cancer drug market 2020 (USD MM) · 34130 US prostate cancer deaths annually 2021
Prostate cancer is the most commonly diagnosed non-skin malignancy in US men, with the American Cancer Society projecting 248,530 new cases and 34,130 deaths in 2021. Approximately 8-10% of men present with metastatic disease at diagnosis (~20,000-25,000 incident metastatic cases annually) and an additional 30-40% of localized patients eventually progress to advanced disease, producing a prevalent advanced prostate cancer population in the US of roughly 200,000-300,000 men receiving androgen deprivation therapy (ADT) at any time. ADT — through medical castration via GnRH agonists or antagonists, or surgical orchiectomy — has been the foundation of advanced disease management for over 80 years, beginning with leuprolide (Lupron) in 1985. Cardiovascular events are a leading cause of non-cancer mortality in this population (≈30% of deaths), and the meta-analysis of relugolix's HERO Phase 3 trial (NEJM 2020) demonstrated a 54% lower risk of major adverse cardiovascular events versus leuprolide. Relugolix received FDA approval as Orgovyx on December 18, 2020 (10 days before the Pfizer deal), making it the first and only oral GnRH antagonist for advanced prostate cancer.
The advanced prostate cancer ADT and intensification market at deal date (Dec 2020) was crowded with established and emerging modalities. Injectable GnRH agonists dominated foundational ADT — AbbVie's Lupron Depot (leuprolide acetate, $720M US 2020), TerSera/AstraZeneca's Zoladex (goserelin), Tolmar's Eligard (leuprolide), and Ferring's Firmagon (degarelix, the only injectable GnRH antagonist) — collectively a ~$2B+ US market. Orgovyx's oral once-daily mechanism and superior cardiovascular profile positioned it as a potential ADT category disruptor. Layered on top of ADT backbone in mCRPC and mHSPC: AR-targeted oral agents Xtandi (enzalutamide, Astellas/Pfizer; $4.9B global 2020), Zytiga (abiraterone, J&J; $2.5B global 2020 pre-generic), Erleada (apalutamide, J&J; $719M 2020), Nubeqa (darolutamide, Bayer/Orion; $58M 2020 launch). PARP inhibitors entered space mid-2020: Lynparza (olaparib, AstraZeneca/Merck) approved May 2020 for HRR-mutated mCRPC, and Rubraca (rucaparib, Clovis) approved May 2020. Radiopharmaceuticals: Pluvicto (Lu-177-PSMA-617, Novartis) Phase 3 VISION readout pending, Xofigo (radium-223). Chemotherapy: docetaxel (generic), Jevtana (cabazitaxel, Sanofi). The Pfizer-Myovant deal positioned Pfizer to leverage its Xtandi commercial infrastructure to drive Orgovyx as the new ADT standard while accessing the relugolix combo tablet for women's health (uterine fibroids approved May 2021, endometriosis Aug 2022).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Myovant Sciences Ltd. (this deal) | 2020 | $4.2B | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2020 deals · Pfizer Inc. deals · Oncology deals